Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen

Oncogene volume 30, pages 2789–2797 (2011)Cite this article

Subjects

Abstract

To overcome imatinib resistance, more potent ABL tyrosine kinase inhibitors (TKIs), such as nilotinib and dasatinib have been developed, with demonstrable preclinical activity against most imatinib-resistant BCR–ABL kinase domain mutations, with the exception of T315I. However, imatinib-resistant patients already harboring mutations have a higher likelihood of developing further mutations under the selective pressure of potent ABL TKIs. NVP-AUY922 (Novartis) is a novel 4,5-diaryloxazole adenosine triphosphate-binding site heat shock protein 90 (HSP90) inhibitor, which has been shown to inhibit the chaperone function of HSP90 and deplete the levels of HSP90 client protein including BCR–ABL. In this study, we investigated the combined effects of AUY922 and nilotinib on random mutagenesis for BCR–ABL mutation (Blood, 109; 5011, 2007). Compared with single agents, combination with AUY922 and nilotinib was more effective at reducing the outgrowth of resistant cell clones. No outgrowth was observed in the presence of 2 μM of nilotinib and 20 nM of AUY922. The observed data from the isobologram indicated the synergistic effect of simultaneous exposure to AUY922 and nilotinib even in BaF3 cells expressing BCR–ABL mutants including T315I. In vivo studies also demonstrated that the combination of AUY922 and nilotinib prolonged the survival of mice transplanted with mixture of BaF3 cells expressing wild-type BCR–ABL and mutant forms. Taken together, this study shows that the combination of AUY922 and nilotinib exhibits a desirable therapeutic index that can reduce the in vivo growth of mutant forms of BCR–ABL-expressing cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Azam M, Latek R, Daley GQ . (2003). Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112: 831–843.

    Article  CAS  Google Scholar 

  • Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S et al. (2007). Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotech 25: 1035–1044.

    Article  CAS  Google Scholar 

  • Branford S, Melo JV, Hughes PT . (2009). Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114: 5426–5435.

    Article  CAS  Google Scholar 

  • Brough PA, Aherne W, Barril X, Borgogononi J, Boxall K, Cansfield JE et al. (2008). 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 51: 196–218.

    Article  CAS  Google Scholar 

  • Deguchi Y, Kimura S, Ashihara E, Niwa T, Hodohara K, Fujiyama Y et al. (2008). Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 32: 980–983.

    Article  CAS  Google Scholar 

  • Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M et al. (2008). NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68: 2850–2860.

    Article  CAS  Google Scholar 

  • Garg RJ, Kantarjian H, O'Brien S, Quintas-Cardama A, Faderl S, Estrov Z et al. (2009). The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 114: 4361–4368.

    Article  CAS  Google Scholar 

  • Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL . (2002). BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 100: 3041–3044.

    Article  CAS  Google Scholar 

  • Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O'Brien S et al. (2008). Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112: 53–55.

    Article  CAS  Google Scholar 

  • Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y et al. (2001). In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97: 1999–2007.

    Article  CAS  Google Scholar 

  • Kantarjian H, Cortes J, Kim D-W, Dorlhiac-Llacer P, Pasquini R, DiPersio J et al. (2009). Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 113: 6322–6329.

    Article  CAS  Google Scholar 

  • Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brian S, Wassmann B et al. (2006). Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354: 2542–2551.

    Article  Google Scholar 

  • Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki P, Jootar S et al. (2007). Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109: 5143–5150.

    Article  CAS  Google Scholar 

  • Matsuyama W, Wang L, Farrar WL, Faure M, Yoshimura T . (2004). Activation of discoidin domain receptor 1 isoform b with collagen up-regulates chemokine production in human macrophages: role of p38 mitogen-activated protein kinase and NF-kappa B. J Immunol 172: 2332–2340.

    Article  CAS  Google Scholar 

  • Nunoda K, Tauchi T, Takaku T, Okabe S, Akahane D, Sashida G et al. (2007). Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors. Oncogene 26: 4179–4188.

    Article  CAS  Google Scholar 

  • O'Hare T, Eide CA, Deininger MWN . (2007). Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110: 2242–2249.

    Article  CAS  Google Scholar 

  • Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA et al. (2007). Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 110: 2309–2315.

    Article  CAS  Google Scholar 

  • Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD . (2007). Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 109: 5011–5015.

    Article  CAS  Google Scholar 

  • Rix U, Hantschel O, Dumberger G, Remsing Rix LL, Planyavsky M, Feenbach NV et al. (2007). Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110: 4055–4063.

    Article  CAS  Google Scholar 

  • Shah NP, Tran C, Lee FY, Chen P, Norris D, Saywers CL . (2004). Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399–401.

    Article  CAS  Google Scholar 

  • Stuhmer T, Zollinger A, Siegmund D, Chatterjee M, Grella E, Knop S et al. (2008). Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia 22: 1604–1612.

    Article  CAS  Google Scholar 

  • Tauchi T, Boswell HS, Leibowitz D, Broxneyer HE . (1994). Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway. J Exp Med 179: 167–175.

    Article  CAS  Google Scholar 

  • Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. (2005). Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7: 129–141.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by a ‘High-Tech Research Center’ Project for private universities: matching fund subsidy from the MEXT (Ministry of Education, Culture, Sports, Science and Technology), and by the ‘University-Industry Joint Research Project’ for private universities: matching fund subsidy from the MEXT.

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan

    T Tauchi, S Okabe & K Ohyashiki

  2. Department of Molecular Cell Physiology, Kyoto Prefectural University of Medicine, Kyoto, Japan

    E Ashihara

  3. Division of Hematology, Department of Internal Medicine, Respiratory Medicine and Oncology, Faculty of Medicine, Saga University, Saga, Japan

    S Kimura

  4. Department of Transfusion Medicine and Cell Therapy, Faculty of Medicine, Kyoto University, Kyoto, Japan

    T Maekawa

Authors
  1. T Tauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Okabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Ashihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Kimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Maekawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Ohyashiki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Tauchi.

Ethics declarations

Competing interests

TT receives research support from Novartis Pharma K.K.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tauchi, T., Okabe, S., Ashihara, E. et al. Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen. Oncogene 30, 2789–2797 (2011). https://doi.org/10.1038/onc.2011.3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2011.3

Keywords

This article is cited by

Search

Advanced search

Quick links